CSL acquires option to Pevion's candidiasis vaccine
This article was originally published in Scrip
Executive Summary
In the first deal for the product, CSL has acquired the right of first refusal to a licence to commercialise Pevion Biotech's therapeutic vaccine against Candida albicans, PEV7, in Australia and New Zealand.
You may also be interested in...
Kyowa Kirin’s Parkinson’s Successor Shows Phase IIb Promise
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Asia Executives On The Move: Sanofi's Global R&D Head Moves To Innovent
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports